Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis
- PMID: 14501378
- DOI: 10.1097/00001813-200309000-00001
Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis
Abstract
Viral oncolysis, or virotherapy, is an endeavor to use viruses as therapeutic agents in an effort to exploit their highly evolved qualities of host cell killing and simultaneous multiplication and spread. This review describes the concept of oncolytic adenoviruses, also called conditionally replicative adenoviruses (CRAds), and recent developments--inspired by early clinical results--that aim at the optimization of CRAd efficacy. Molecular strategies applied for the development of oncolytic adenoviruses include (i) the genetic manipulation of the expression and/or function of key regulatory viral proteins in order to restrict viral replication and spread to tumor cells, (ii) the engineering of the adenoviral capsid for efficient and tumor-targeted infection, and (iii) the incorporation of heterologous genes to facilitate combination therapies or tracking of the virus. Initial clinical trials have provided proof-of-concept for adenoviral oncolysis in patients and a favorable safety profile for oncolytic adenoviruses has been demonstrated. In conclusion, adenoviral oncolysis, with its distinct therapeutic mechanism, shows remarkable therapeutic potential. Advanced generations of virotherapeutics are currently in development.
Similar articles
-
Engineering regulatory elements for conditionally-replicative adeno-viruses.Curr Gene Ther. 2003 Aug;3(4):357-85. doi: 10.2174/1566523034578311. Curr Gene Ther. 2003. PMID: 12871022 Review.
-
A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.Int J Mol Med. 2006 Oct;18(4):751-9. Int J Mol Med. 2006. PMID: 16964432 Free PMC article.
-
Cancer gene therapy with oncolytic adenoviruses.J BUON. 2009 Sep;14 Suppl 1:S7-15. J BUON. 2009. PMID: 19785073 Review.
-
Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.Int J Oncol. 2008 Jun;32(6):1179-88. doi: 10.3892/ijo_32_6_1179. Int J Oncol. 2008. PMID: 18497979
-
[Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].Mol Biol (Mosk). 2012 Jul-Aug;46(4):556-69. Mol Biol (Mosk). 2012. PMID: 23113343 Review. Russian.
Cited by
-
Adenovirus gene transfer to amelogenesis imperfecta ameloblast-like cells.PLoS One. 2011;6(10):e24281. doi: 10.1371/journal.pone.0024281. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22003382 Free PMC article.
-
E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer.Dig Dis Sci. 2009 Jul;54(7):1425-31. doi: 10.1007/s10620-008-0543-0. Epub 2008 Nov 26. Dig Dis Sci. 2009. PMID: 19034663
-
Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.Oncotarget. 2016 Feb 23;7(8):9046-59. doi: 10.18632/oncotarget.7031. Oncotarget. 2016. PMID: 26824985 Free PMC article.
-
Gene therapy, early promises, subsequent problems, and recent breakthroughs.Adv Pharm Bull. 2013;3(2):249-55. doi: 10.5681/apb.2013.041. Epub 2013 Aug 20. Adv Pharm Bull. 2013. PMID: 24312844 Free PMC article.
-
Oncolytic viruses: From bench to bedside with a focus on safety.Hum Vaccin Immunother. 2015;11(7):1573-84. doi: 10.1080/21645515.2015.1037058. Hum Vaccin Immunother. 2015. PMID: 25996182 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
